Arcutis (ARQT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
Chief Commercial Officer — Todd Edwards Chief Medical Officer — Patrick E. Burnett Chief Financial Officer — Latha Vairavan Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript Frank Watanabe: Thanks, Brian, and thanks, everyone, for joining us today. I want to start out today's call by reviewing some key highlights and achievements from 2025, a year that I would characterize as one of tremendous growth and progress for Arcutis Biotherapeutics, Inc. as we pursue our mission of serving individuals living with chronic inflammatory skin conditions. We will then transition to Todd for a commercial update, then Patrick for an R&D update, and Latha for a review of our financial results. So in 2025, we made significant strides to solidify Arcutis Biotherapeutics, Inc.'s position as one of the industry's foremost leaders in delivering meaningful innovation in medical dermatology. Throughout the year, we saw robust net product sales revenue gr
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone [Yahoo! Finance]Yahoo! Finance
- Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth [Yahoo! Finance]Yahoo! Finance
- Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of GrowthGlobeNewswire
- Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen [Yahoo! Finance]Yahoo! Finance
- Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis [Yahoo! Finance]Yahoo! Finance
ARQT
Earnings
- 2/25/26 - Beat
ARQT
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/3/26 - Form 4
- ARQT's page on the SEC website